Company Quick10K Filing
Encision
10-Q 2019-12-31 Filed 2020-02-13
10-Q 2019-09-30 Filed 2019-11-13
10-Q 2019-06-30 Filed 2019-08-14
10-K 2019-03-31 Filed 2019-06-14
10-Q 2018-12-31 Filed 2019-02-14
10-Q 2018-09-30 Filed 2018-11-13
10-Q 2018-06-30 Filed 2018-08-13
10-K 2018-03-31 Filed 2018-06-14
10-Q 2017-12-31 Filed 2018-02-12
10-Q 2017-09-30 Filed 2017-11-13
10-Q 2017-06-30 Filed 2017-08-08
10-K 2017-03-31 Filed 2017-06-14
10-Q 2016-12-31 Filed 2017-02-14
10-Q 2016-09-30 Filed 2016-11-14
10-Q 2016-06-30 Filed 2016-08-11
10-K 2016-03-31 Filed 2016-06-14
10-Q 2015-12-31 Filed 2016-02-08
10-Q 2015-09-30 Filed 2015-11-12
10-Q 2015-06-30 Filed 2015-08-12
10-K 2015-03-31 Filed 2015-06-19
10-Q 2014-12-31 Filed 2015-02-06
10-Q 2014-09-30 Filed 2014-11-13
10-Q 2014-06-30 Filed 2014-08-12
10-K 2014-03-31 Filed 2014-06-26
10-Q 2013-12-31 Filed 2014-02-11
10-Q 2013-09-30 Filed 2013-11-13
10-Q 2013-06-30 Filed 2013-08-13
10-K 2013-03-31 Filed 2013-06-28
10-Q 2012-12-31 Filed 2013-01-31
10-Q 2012-09-30 Filed 2012-11-02
10-Q 2012-06-30 Filed 2012-07-31
10-K 2012-03-31 Filed 2012-05-16
10-Q 2011-12-31 Filed 2012-02-06
10-Q 2011-09-30 Filed 2011-11-14
10-Q 2011-06-30 Filed 2011-08-04
10-K 2011-03-31 Filed 2011-06-15
10-Q 2010-12-31 Filed 2011-01-31
10-Q 2010-09-30 Filed 2010-10-28
10-Q 2010-06-30 Filed 2010-08-11
10-K 2010-03-31 Filed 2010-06-04
10-Q 2009-12-31 Filed 2010-02-12
8-K 2020-02-06 Exhibits
8-K 2019-11-06 Exhibits
8-K 2019-08-14 Shareholder Vote
8-K 2019-08-12 Exhibits
8-K 2019-02-07 Exhibits
8-K 2019-01-03 Enter Agreement, Sale of Shares, Exhibits
8-K 2019-01-03 Enter Agreement, Sale of Shares, Exhibits
8-K 2019-01-02 Exhibits
8-K 2018-11-06 Exhibits
8-K 2018-08-10 Shareholder Vote
8-K 2018-08-07 Enter Agreement, Off-BS Arrangement
8-K 2018-08-02 Exhibits
8-K 2018-05-07 Exhibits
8-K 2018-02-05 Exhibits

Encision Financials

ECIA Metrics, Comps, Filings

Quarterly | Annual

Business

Encision Inc. (“Encision”, “we”, “us”, “our” or the “Company"), a medical device company based in Boulder, Colorado, has developed and markets innovative technology that provides unprecedented outcomes and patient safety in minimally-invasive surgery. We believe that our patented Active Electrode Monitoring (AEM®) Surgical Instruments are changing the marketplace for electrosurgical devices and laparoscopic instruments by providing a solution to a well-documented hazard unique to laparoscopic surgery.

We address market opportunities created by the increase in minimally-invasive surgery (“MIS”) and surgeons' use of electrosurgery devices in these procedures. The product opportunity exists in that monopolar electrosurgery instruments used in laparoscopic procedures provide excellent clinical results, but are also susceptible to causing inadvertent collateral tissue damage outside the surgeon's field of view. The risk of unintended electrosurgical burn injury to the patient in laparoscopic surgery has been well documented. This risk poses a threat to patient safety, including the risk of death, and creates liability exposure for surgeons and hospitals, and increased and preventable readmissions. Our technology helps to reduce hospital risk and liability.

Our patented AEM technology provides surgeons with the desired tissue effects of cutting and coagulating tissue in laparoscopic procedures, while preventing stray electrosurgical energy that can cause complications and even death. AEM Surgical Instruments are equivalent to conventional instruments in size, shape, ergonomics and functionality, but they incorporate a proprietary shield and electrically connect to an Active Electrode Monitor to dynamically and continuously monitor the flow of electrosurgical current, thereby preventing patient injury from stray monopolar energy. With our “shielded and monitored” instruments, surgeons are able to perform electrosurgical procedures more safely, effectively and economically than is possible using conventional instruments.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Quarterly)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Quarterly)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Oculus (OVTZ) 5,362 -19.3 -62% 414 137 0 0 -257 -257 4,949
Propanc Biopharma (PPCB) 983 -1.0 -2,593% 198 4,739 0 -24 -5,125 -3,561 3,434
Creative Learning (CLCN) 3,848 0% 2.2 61% 2,700 5,017 4,008 0 1,644 1,644 3,559
Nuo Therapeutics (AURX) 3,796 69% -2.2 -1,173% 154 1,347 344 236 -1,810 -1,734 3,787
Patriot Gold (PGOL) 4,463 0% 25.7 9% 1,935 226 436 0 166 166 4,261
Encision (ECIA) 3,709 51% -115.6 -4% 4,148 1,933 8,055 4,147 -152 -31 3,568
Innovus Pharmaceuticals (INNV) 5,796 65% -2.1 -63% 9,514 11,510 17,966 11,617 -5,984 -3,875 8,027
Blake Insomnia Therapeutics (BKIT) 3,681 -135.2 0 237 0 0 -27 -27 3,681
Geospatial (GSPH) 3,709 70% -6.3 -736% 111 3,656 273 190 -816 -586 3,668
Visium Technologies (VISM) 0 0.0 -31,116% 3 3,141 0 0 -796 -796 -3
Cartesian (CRTN) 3,632 30% -0.4 -44% 16,522 17,461 47,555 14,053 -7,270 -5,582 2,087
GraniteShares Platinum Trust (PLTM) 5,316 12.8 7% 5,803 2 0 0 415 415 5,316
Invesco CurrencyShares Singapore Dollar Trust (FXSG) 3,628 0% -50.4 1% 3,558 1 40 0 26 26 -1,288
Fieldpoint Petroleum (FPP) 3,628 0% 13.8 -5% 4,528 6,259 1,668 0 -241 247 3,414
American Church Mortgage (ACMC) 3,339 2.4 -0% 39,246 28,836 0 0 -48 1,343 3,218
Immune Pharmaceuticals (IMNP) 3,597 -0.9 -71% 20,716 19,874 0 0 -14,715 -13,953 12,494
American Bio Medica (ABMC) 3,580 35% -28.9 -20% 2,246 2,809 2,776 971 -440 -177 5,119
Empire Petroleum (EMPR) 3,576 0% -3.0 -30% 11,795 13,670 4,941 0 -3,541 -3,815 11,553
Genesis Financial (GFNL) 3,571 0% -1.1 -155% 2,427 3,394 10 0 -3,756 -3,242 3,551
Frontier Oilfield Services (FOSI) 3,542 0% -5.7 -319% 868 11,161 646 0 -2,768 -2,021 11,479

Balance Sheet ($'000)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash18815656546355847312694511,5201,6901,1471,039688259125113107293473264507912921311553187602298136142
Accounts Receivable1,1591,1011,4271,4281,2871,0851,0969861,0181,0311,0608639377901,0149659098718628409459651,0791,0429849219379631,2511,1071,0241,0091,021968
Inventory2,6932,6882,6772,4892,3782,4722,6222,9292,9202,7912,6572,2242,1602,1172,0882,3382,1951,9742,0011,7311,7101,4581,1361,1281,2011,2141,2471,4371,2361,3681,3911,4731,3781,343
PP&E1,2781,3801,5291,6191,6141,6541,6601,6291,7961,6991,8181,1051,024946853777701638590561531516513468439396377349314281239250234225
Assets5,7475,5785,9866,4096,1796,1596,1885,9836,2655,9717,4296,2115,7905,3765,1304,7264,3603,9923,9643,8103,7063,3903,2283,0673,1293,1203,2293,2523,2803,3223,6593,4284,3454,148
Accounts Payable7557281,1161,040452728693823442612386666471545581675498464443356444289508403394406522466450569690579438313
Long-Term Debt
Liabilities2,2692,7481,6721,1841,4191,5201,5892,0951,9101,3561,6231,3901,3751,5291,4581,2881,0851,2371,3481,3251,2321,3261,2641,1309861,0231,0491,0461,0621,1221,0762,1681,933
Stockholders' Equity3,3093,2384,7374,9944,7404,6684,3944,1704,0616,0734,5884,4004,0013,6013,2683,0722,9082,7262,4622,3802,1581,9021,8031,9992,1332,2062,2042,2352,2602,5372,3522,1772,215
Income Statement ($'000)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue3,1843,2673,1672,8733,1012,9233,0552,6502,6822,6452,7162,5042,4762,2792,6082,3072,4542,3002,2932,2892,2772,1512,2302,2122,3642,1632,1902,0382,4042,1972,1172,0841,9291,924
Cost of Revenue1,4051,7011,4261,4321,3531,2621,3891,2281,1531,2381,2922,4121,2541,2041,3931,1261,2811,1201,1191,2401,0871,1421,1651,0701,0199049578671,1039911,055981996875
Gross Profit1,7791,5661,7411,9391,7481,6121,6661,5081,5281,4071,424921,2221,0751,2161,1811,1741,1801,1741,0491,1901,0091,0641,1421,3441,2591,2341,1711,3011,2731,0621,1039331,049
R&D331342338338343482461462388316364340315358353316284306340320302279300246221190224207167187189237236173
SG&A1,4561,6761,4651,5511,3951,5181,2881,2611,3041,0699621,1491,0531,1731,2251,1771,0639969809969749741,0229989259399389661,0961,1849571,047876841
Tax00000000000000000000000000000000
Net Income-21-18230
Cash Flow ($'000)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating4814328-263217-2-269-649205266290-500-103-433-397-12969-207101-128-3516223108267120-142204-29188
Cash Investing-179-217-158-72-117-78-69-108-57-226-69-42-6-2-13-5-17-35-42-39-41-46-8-30-10-36-6-8-22-24
Cash Financing20065689233-6-5-9725-1911,428-52-20236127-7959-84-34-43-207087-87150-57